

28<sup>th</sup> July, 2025

**BSE Limited**  
P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

**Grant of stock options pursuant to Piramal Pharma Limited - Employee Stock Option and Incentive Plan 2022 ('Plan 2022')**

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III to the SEBI Listing Regulations, we wish to inform you that the Nomination and Remuneration Committee of the Board of Directors of the Company at its meeting held on Monday, 28<sup>th</sup> July, 2025 approved grant of 20,20,507 stock options under the Plan 2022.

The disclosure as required under Regulation 30 of SEBI Listing Regulations is enclosed herewith as Annexure-1.

You are requested to take the above information on your record.

Thanking you,

Yours truly,  
For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**  
**Encl: As above**

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070  
India T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

[piramalpharma.com](http://piramalpharma.com)

**Annexure I**

Sr. No.	Particulars	Details
1.	Brief details of options granted	20,20,507 Options under Piramal Pharma Limited – Employee Stock Option and Incentive Plan 2022
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3.	Total number of shares covered by these options	20,20,507 equity shares
4.	Pricing formula	Options have been granted at an exercise price of Rs.10/- per option
5.	Options vested	<p>All location except US</p> <ul style="list-style-type: none"> <li>• 1/3rd would vest on 28 July, 2026 and be exercisable till 27 July, 2031</li> <li>• 1/3rd would vest on 28 July, 2027 and be exercisable till 27 July, 2032</li> <li>• 1/3rd would vest on 28 July, 2028 and be exercisable till 27 July, 2032</li> </ul> <p>And</p> <ul style="list-style-type: none"> <li>• 2/3rd would vest on 28 July, 2026 and be exercisable till 27 July, 2031</li> <li>• 2/3rd would vest on 28 July, 2027 and be exercisable till 27 July, 2032</li> </ul> <p>US</p> <ul style="list-style-type: none"> <li>• 1/3rd would vest on 28 July, 2026 and be exercisable till 15th March, 2027</li> <li>• 1/3rd would vest on 28 July, 2027 and be exercisable till 15th March, 2028</li> <li>• 1/3rd would vest on 28 July, 2028 and be exercisable till 15th March, 2029</li> </ul> <p>And</p> <p>US</p> <ul style="list-style-type: none"> <li>• 2/3rd would vest on 28 July, 2026 and be exercisable till 15th March, 2027</li> <li>• 2/3rd would vest on 28 July, 2027 and be exercisable till 15th March, 2028</li> </ul>
6.	Time within which option may be exercised	Options can be exercised within 5 years commencing from the date of vesting of each tranche. For US, Vested Options shall be Exercised within the period mentioned in the schedule above under US Options vested.

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070  
India T: +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)
[piramalpharma.com](http://piramalpharma.com)